

Update on the Copenhagen ASC program

Mandana Haack-Sørensen MSc PhD

CSCC has conducted three clinical studies in patients with IHD w/wo heart failure using their own culture expanded MSCs or ASCs (autologous). The treatment was safe and with a significant clinical effect. However, the use of autologous stem cell is very labour intensive with a huge variation in cell products both in numbers and quality. It is expensive and logistically a challenge because of variation in cultivation periods and transportation of cell products forth and back between the patients and the few approved cell expansion laboratories.

A few studies have compared the use of the patients own MSCs and MSCs from healthy donors (allogeneic) without any detectable difference in clinical efficacy in patients with IHD. Therefore, the clinically approved CSCC_ ASC product and its storage in vials in nitrogen as an off-the-shelf product ready for use will have a significant impact on dissemination of stem cell therapy to many diseases. The product has proven safety in a pilot study and is presently in two larger phase II clinical trials in heart failure patients in Denmark and six European Countries, respectively.